Accretion Pharmaceuticals FY26: ₹9.67 Cr Profit, Minus ₹14.62 Cr From Operations

General information and entertainment, not investment advice. The author is not a SEBI-registered adviser or research analyst. No recommendation, no promised returns. Markets carry risk including loss of capital. Figures may not be current. Consult a registered adviser before acting.

1. At a Glance

Accretion Pharmaceuticals closed FY26 with sales of ₹89.63 crore, up from ₹57.38 crore a year earlier, and a net profit of ₹9.67 crore. On paper, a small Gujarat contract manufacturer compounding fast. Then the cash flow statement arrives and files a dissent: operating activities consumed ₹14.62 crore during the same year the P&L reported record profit.

The gap between the two documents is the whole story. Profit is an opinion formed on the income statement; cash is a fact settled at the bank. For FY26 the two disagree by roughly ₹24 crore.

There is more in the record. A SEBI adjudication order dated 7 January 2026 imposed a ₹1,00,000 penalty over disclosures made before the May 2025 IPO. Operating margin slipped from 20.72% to 16.68%. Receivables climbed to ₹22.4 crore. Promoters — four men holding 17.69% each — control 73.52%.

The company grew revenue 56% and its operating cash balance went underwater. How both are true at once is what the next fourteen sections lay out.

2. Introduction

Accretion Pharmaceuticals was incorporated in 2012 and manufactures pharmaceutical formulations — tablets, capsules, oral liquids, external preparations — out of a single facility in Sanand, Gujarat. It listed on the NSE Emerge SME platform on 21 May 2025, raising ₹29.75 crore via a fresh issue of 29,46,000 shares at ₹101 each.

The business is contract-and-third-party manufacturing for domestic and export markets, serving private institutions, government buyers, and other pharmaceutical companies. Management frames the identity plainly on its earnings call: a CDMO manufacturer, not a front-end brand.

FY26 is the first full year with a listed-company paper trail, and it is a busy one. The IPO closed in the year. Independent directors were appointed at the September 2025 AGM. A SEBI show-cause notice landed in October 2025 and became a ₹1,00,000 penalty order in January 2026. The audited FY26 results were approved by the board on 8 May 2026 with an unmodified auditor opinion from VSSB & Associates.

For a company that only recently acquired an investor-relations department, a fair amount has already happened to it.

3. Business Model: WTF Do They Even Do?

They make other people’s medicines. That is the honest one-line version, and management does not pretend otherwise — on the November 2025 call, Vivek Patel described the company as a CDMO that manufactures “according to demand,” not a brand owner chasing shelf space.

The product mix spans antibiotics, anti-inflammatories, gastro, dermatology, and nutraceuticals across tablets, capsules, oral liquids, and external preparations. Per the DRHP, tablets contributed 41.5% of revenue, oral liquids 28.5%, capsules 15%. The single Sanand plant carried a stated formulation capacity of 1.03 billion units annually.

The export model is the interesting part. Rather than build in-country sales teams, management says it ships directly to importers and distributors — “the bigger player… traditionally working as their supply chain only,” per the CFO. Roughly 70% of revenue is export, 30% domestic, and management clarified the domestic slice is also contract manufacturing, not owned branding. So it is a company that manufactures without marketing, in over 30 countries, under nobody’s name including its own.

Asked which therapy it specialises in, management said none — breadth is the pitch. That is a defensible strategy and also a polite way of saying the moat is the factory. A CDMO’s advantage is capacity, compliance certificates, and working capital to fund the order cycle. Two of those three, as the balance sheet will show, are expensive.

Does a broader product mix protect a contract manufacturer, or just spread the same thin margin across more SKUs?

4. Financials Overview

Figures are consolidated, in ₹ crore. The company reports on a half-yearly basis; the table below compares the March 2026 half against the year-ago half and the immediately preceding one.

Revenue in the half grew 18.2% year-on-year while operating profit rose only 4.5% — the margin did the shrinking. Note the EPS line: net profit rose from ₹4.33 crore to ₹4.92 crore, yet EPS fell from ₹5.30 to ₹4.43. That is not a profit decline. The IPO in May 2025 added shares to the denominator; more owners now split a bigger pie into smaller slices. The share count moved, not the business.

From the concall (Nov 2025): management attributed H1 FY26’s revenue jump to post-IPO capacity, a richer mix of value-added CDMO work, and a wider customer base, while flagging that registration and development costs were holding margins down during ramp-up.

5. Market Expectations & Historical Multiples

This section describes how the market is currently pricing the company and how that compares with its own history and peer group. It is descriptive, not predictive.

The market currently pays 17.9x earnings here, against a peer median of 35.06x and an industry P/E of 35.1x. On returns, the company’s 28.9% ROCE sits well above the peer median of 15.14%.

What the market appears to be pricing is the combination of high stated returns and a short, unproven track record: a company earning peer-beating ROCE but with only two full years of scale, a fresh listing, a regulatory penalty on file, and operating cash flow that has been negative in two of its last three years. The multiple below the peer set reflects those facts sitting on the same page as the growth.

One factual observation on expectations: the market pays roughly half the peer multiple for a company whose returns screen above the peer set — a spread the record’s cash-flow and governance lines are visibly contributing to.

6. What’s Cooking

Real events from the filings, no manufacturing of drama required — the record supplies enough.

The SEBI adjudication order of 7 January 2026 imposed a ₹1,00,000 penalty under Section 15HB. Per the disclosure, SEBI found the management had made forward-looking projections at an investor meet held a day before the IPO opened. The company noted no financial impact beyond the penalty amount.

The IPO utilisation certificate submitted 25 June 2026 confirmed ₹2,975.46 lakh raised, with ₹200 lakh still unutilised and parked in short-term deposits.

Per the November 2025 concall, management announced a Malawi cGMP plant approval from the PMRA, described as opening direct export access to the African market, and stated more than 100 products were under registration across markets.

An investor/analyst meet in Mumbai was scheduled for 26 June 2026. And on 2 July 2026, HR Manager Bandana Kumari resigned for personal reasons — notably, having only been appointed on 8 May 2026. A tenure of under two months is short even by SME standards.

7. Balance Sheet

Assets equal liabilities in every column; the ledger balances.

• Net worth quadrupled to ₹54.71 crore in two years, almost entirely because IPO proceeds landed in reserves — reserves jumped from ₹7.12 crore to ₹43.59 crore. This is capital raised, not capital earned.
• Borrowings actually ticked down to ₹12.32 crore, helped by the IPO object of repaying certain loans. The balance sheet used the equity raise partly to pay off debt — a rare moment of tidiness.
• Against ₹12.32 crore of borrowings sits ₹4.02 crore of cash, leaving the company in a modest net-debt position, not net cash — despite raising ₹29.75 crore during the year.

The equity base ballooned; the cash pile did not. That tells you where the money went.

8. Cash Flow: Sab Number Game Hai

Trace the money and the pattern is unmistakable. Operations generated positive cash exactly once in three years. In FY26 — the record-profit year — operating activities consumed ₹14.62 crore. The ₹27.12 crore financing inflow, largely the IPO, is what kept the closing cash balance positive.

This is the working-capital tax. On the concall management put export working capital at roughly 185–190 days. Receivables and inventory swelled as sales scaled, and every rupee of growth had to be pre-funded before it turned into collected cash. Growth here is not self-financing; it eats cash and waits.

A business can report profit and still run its bank account into the ground for years, because profit counts the sale and cash counts the payment — and in exports, those two events are six months apart.

9. Ratios: Sexy or Stressy?

• ROE of 27.6% and ROCE of 28.9% are the headline attraction — the capital, on these numbers, is working hard.
• But ROE is flattered in transition years: FY26’s equity base only just absorbed ₹29.75 crore of fresh IPO capital, and a full year of that enlarged base has not yet dragged the ratio down.
• D/E of 0.23 is comfortable, sitting alongside interest coverage the data sheet puts at 16.4x — the debt load itself is not the pressure point.
• PAT margin of 10.8% is respectable for contract manufacturing, though it earns cash only on paper until the receivables clear.

High return ratios and negative operating cash flow can coexist for exactly as long as someone keeps funding the gap.

10. P&L Breakdown: Show Me the Money

The good news first: this is real operating profit, not a mirage of other income. Other income of ₹0.19 crore against operating profit of ₹14.95 crore is a rounding error — the profit is the actual business, which is more than many small caps can claim.

The trajectory: revenue up nearly seven-fold in two years, operating profit up nearly six-fold. But operating profit grew slower than revenue in FY26 — margins compressed from 20.72% to 16.68%. Per the concall, management attributed the softer margin to product-mix shift toward volume and to ongoing registration and development costs during expansion.

On EPS: it rose only from ₹8.31 to ₹8.70 despite PAT climbing from ₹6.79 crore to ₹9.67 crore. The share count expanded with the IPO, so per-share earnings grew far slower than total earnings — a dilution effect, not a profitability stumble.

11. Peer Comparison

The scale gap is almost comic — Accretion’s full quarterly revenue of ₹45.89 crore is a fraction of what Sun Pharma books in profit alone. On multiple, Accretion trades at the lowest P/E in this set, 17.89x against a peer median of 35.06x. It also posts a 28.9% ROCE that outranks most of the listed giants. The market is applying a small-cap-illiquidity-and-track-record discount to a company that, on the return ratios alone, screens ahead of the room. Both facts are on the same table.

12. Miscellaneous: Shareholding & Promoters

The promoter block is unusually flat: four individuals — Vivek Ashok Kumar Patel, Hardik Mukundbhai Prajapati, Harshad Nanubhai Rathod, and Mayur Popatlal Sojitra — each hold exactly 17.69%. Four equal partners, no single controlling hand. Vivek Patel serves as Managing Director.

Institutional holding has drained to zero: FIIs held 2.22% in June 2025 and 0.00% by March 2026; DIIs did the same. The float is now entirely promoters and public.

On the promoter record, the relevant fact is conduct, not identity: the SEBI penalty over pre-IPO forward-looking projections attaches to management’s disclosure behaviour at the very start of the company’s listed life.

13. Corporate Governance: Angels or Devils?

The record here is mixed rather than alarming. On the clean side: the FY26 statutory audit carried an unmodified opinion from VSSB & Associates, no share pledges were disclosed, and the promoters filed a nil-encumbrance declaration for FY25-26.

On the flagged side, three facts stand on their own. First, the SEBI adjudication order — a ₹1,00,000 penalty for forward-looking projections at an investor meet a day before the IPO opened. Second, the data sheet flags that the company might be capitalising interest cost, which shifts expense off the P&L and onto the balance sheet. Third, the HR Manager appointed on 8 May 2026 resigned on 2 July 2026 — under two months, for stated personal reasons.

The company also pays no dividend despite repeated profits, choosing to retain everything to feed a working-capital cycle that, as the cash flow shows, is hungry.

14. Industry Roast & Macro Context

The CDMO export game is a working-capital business wearing a pharmaceutical costume. You manufacture on credit, ship across an ocean, register your plant in a country that takes one-to-two years to say yes (per management’s own timeline), then wait 185-odd days to be paid. The margin is real; the patience required to collect it is the actual product.

Semi-regulated African and Southeast Asian markets reward exactly this profile — flexible, broad-mix, certificate-heavy manufacturers who will chase a Malawi or Rwanda registration that bigger players find too small to bother with. The trade-off is structural: registration costs recur as you enter each new market, so the expense line management flagged as “ramp-up” is arguably just the cost of the strategy, permanently. In a sector where the giants measure quarterly profit in thousands of crores, a ₹173 crore contract manufacturer competes on being nimble enough to serve orders nobody else wants to.

15. EduInvesting Verdict

Accretion is a genuine puzzle: a company whose income statement compounds and whose cash flow statement bleeds, sitting under a multiple half its peer group’s. The return ratios say it earns well; the cash flow says it hasn’t yet been paid for it; the SEBI file says its first act as a public company drew a regulator’s pen.

A profit-and-loss account that keeps rising, and a bank balance that only stays positive because the IPO cheque cleared.